The mean duration in the TOX state was approximately 3.5 weeks in the panitumumab+BSC group compared with 1.1 weeks for the BSC alone treatment group (P=0.0006); however, patients on panitumumab+BSC spent 13.3 weeks in the TWiST state compared with 8.0 weeks for patients on BSC alone and the difference of 5.3 weeks was statistically significant (P<0.0001).
All fractures (100%% of patients) united (Figs. 5, 6, 7) in a mean duration of 7.2 weeks (range 5 10 weeks), as shown in Table 1.
All fractures united in a mean duration of 7.2 weeks (range 5 10 weeks) with no secondary displacement or mal-union.
In this study, the time to regain the normal ROM ranged from 8to2020 weeks with a mean duration of 13 weeks, with faster recovery in patients with less immobilization.
The duration of treatment ranged from 21 to 65 weeks, with a mean duration of 44.5 weeks.
Two trials evaluated pioglitazone to placebo in 144 subjects over a mean duration of 50 weeks [ 39, 51].
Monotony in weekly training duration was computed as "mean duration per week" divided by the "standard deviation duration per week".
Weight loss occurred in both groups, but was greater in the medication group: the carbohydrate-restricted group lost a mean of 9.5 kg over 15.0 weeks (0.63 kg/week); the low-fat/low-calorie diet + medication group lost a mean of 14.1 kg over a mean duration of 20.2 weeks (0.70 kg/week), p < 0.01.
Three patients experienced stable disease (SD) with a mean duration of 37 weeks.
All were hospitalized to receive intravenous antibiotic therapy (mean duration, 2 weeks) for acute respiratory exacerbations.
In another recent RCT (n = 82) from Australia, adolescent patients were randomized either to hospitalization for medical stabilization (mean duration: 3 weeks, mean %EBW at discharge: 84) or for weight restoration (mean duration: 5 weeks, mean %EBW at discharge: 92), thus comparing short and slightly longer inpatient treatment.
